HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Conditions
Keywords
Hormone Receptor (HR) Positive Breast Cancer, Estrogen receptor (ER) positive, Progesterone receptor (PR) positive, Cyclin-dependent kinase (CDK), Human epidermal growth factor receptor 2 (HER2) negative, Advanced breast cancer, Metastatic breast cancer (MBC), Triple negative breast cancer (TNBC), Epithelial ovarian cancer (EOC), Fallopian tube cancer, Primary peritoneal cancer (PPC), CDK4/6 inhibitor, Endocrine Therapy (ET), Measurable disease, Luteinizing Hormone Releasing Hormone (LHRH) Agonist, Goserelin, Leuprolide acetate
Brief summary
The purpose of this clinical trial is to learn about the safety and effects of study medicine (PF-06873600) when taken alone or with hormone therapy by people with cancer. People may be able to participate in this study if they have the following types of cancer: Hormone Receptor positive (HR+) breast cancer; Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer that is advanced or metastatic (spread to other parts of the body); triple negative breast cancer; epithelial ovarian cancer; fallopian tube cancer; or primary peritoneal cancer. All participants in this study will receive the study medicine by mouth, 1 to 2 times a day at home. The dose of the study medicine may be changed during the study. Some participants will also receive hormone therapy. The hormone therapy will be either letrozole by mouth once a day at home, or fulvestrant as a shot into the muscle. Fulvestrant will be given every two weeks at the study clinic for the first month, and then once a month after that. Participants will take part in this study for at least 7 to 8 months, depending on how they respond to the therapy. During this time participants will visit the study clinic once a week for the first 2 cycles and every cycle thereafter.
Detailed description
This is a Phase 1/2a, open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamic study of PF-06873600 administered as a single agent in sequential dose levels and then in combination with endocrine therapy. In Part 1A and Part 1C, successive cohorts of patients will receive escalating doses of PF-06873600 and then in dose finding (Part 1B) with PF-06873600 in combination with endocrine therapy (ET). This study contains 2 parts, dose escalation with single agent (Part 1A and 1C) and then dose finding with PF-06873600 in combination with endocrine therapy (Part 1B) followed by dose expansion arms of PF-06873600 in combination with endocrine therapy (Part 2).
Interventions
DRUGPF-06873600
PF-06873600 tablet for oral dosing
Endocrine Therapy 1
DRUGEndocrine Therapy 2
Endocrine Therapy 2
Sponsors
Pfizer
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 Negative (HER2-) breast cancer • Prior combined CDK 4/6 inhibitor and endocrine therapy and 1 or 2 prior lines of chemotherapy * Have a diagnosis of metastatic triple negative breast cancer (TNBC) • Up to 1-2 prior lines of chemotherapy * Have a diagnosis of advanced platinum resistant epithelial ovarian cancer (EOC)/fallopian tube cancer/primary peritoneal cancer (PPC) • Up to 2-3 prior lines of therapy * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1 * Measurable disease or non-measurable disease and refractory to or intolerant of existing therapies (Part 1) * Measurable disease as defined by RECIST 1.1 is required (Part 1B and Part 2 only)
Exclusion criteria
* Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases * Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ * Major surgery or radiation within 4 weeks prior to study entry * Last anti-cancer treatment within 2 weeks prior to study entry * Participation in other studies involving investigational drug(s) within 4 weeks prior to study entry * Pregnant or breastfeeding female patients * Active inflammatory gastrointestinal (GI) disease, known diverticular disease or previous gastric resection or lap band surgery including impairment of gastro intestinal function or GI disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) - Part 1 | Cycle 1 (within 28 days after the first dose of study intervention) | DLT was defined as any of the following adverse events (AEs) occurring in the first cycle of treatment (28 days) which were attributable to one, the other, or both agents in the combination: Hematologic - grade(G) 4 neutropenia lasting \>7 days; Febrile neutropenia defined as an absolute neutrophil count (ANC) \<1.0 \* 10\^9/L with a single temperature of \>38.3°C, or a sustained temperature of ≥38°C, for more than 1 hour; G≥3 neutropenia with associated infection; G3 thrombocytopenia with clinically significant bleeding as indicated by ≥ G2 bleeding; G4 thrombocytopenia. Nonhematologic: Confirmed case of Drug Induced Liver Injury (DILI) (Hy's Law); G≥3 AEs that were clinically significant. |
| Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Day 1 up to 28 days after the last dose of study intervention, up to approximately 24 months | An AE was defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after participants' signed informed consent has been obtained. An SAE was an AE resulting in any of the following outcomes: was fatal or life-threatening; resulted in persistent or significant disability/incapacity; constituted a congenital anomaly/birth defect; was medically significant; required inpatient hospitalization or prolongation of existing hospitalization. Treatment Related AEs were treatment emergent AEs with cause categorized by the investigator as related to study treatment. |
| Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Day 1 up to 28 days after the last dose of study intervention, up to approximately 24 months | Severity was graded as NCI CTCAE version 4.03:Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. |
| Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Day 1 up to 28 days after the last dose of study intervention, up to approximately 24 months | Severity was graded as NCI CTCAE version 4.03:Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE. |
| Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Day 1 up to 28 days after the last dose of study intervention, up to approximately 24 months | Pre-defined criteria included: 1) systolic blood pressure (SBP) (mm Hg) minimum (min) value \<90; 2) SBP change from baseline (CFB) (mm Hg) maximum (max) decrease \>=30 or max increase \>=30; 3) diastolic blood pressure (DBP) (mm Hg) min \<50; 4) DBP CFB (mm Hg) max decrease \>=20 or max increase \>=20; 5) supine heart rate (HR) beats per minute (bpm) min \<40 or max \>120. |
| Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | Day 1 up to 28 days after the last dose of study intervention, up to approximately 24 months | ECG pre-defined categories for QTc interval adjusted according to Fridericia formula (QTcF) (msec) included: 450 \<= max. \<=480, 481 \<= max. \<=500, max \>=501; QTcF CFB: 30 \< max \<=60, max \>60; for PR and QRS: PR (msec): max \>=300; PR increase from baseline: Baseline \>200 and max. \>=25% increase, Baseline \<=200 and max. \>=50% increase; QRS (msec): max \>=200; QRS (msec) increase from baseline: Baseline \>100 and max. \>=25% increase, Baseline \<=100 and max. \>=50% increase. Categories, with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure. |
| Overall Response Rate (ORR): Part 2 | From the start of the treatment until disease/clinical progression or death or early study discontinuation, whichever happened earlier (approximately up to 24 months) | ORR: percentage of participants with confirmed complete response (CR) or partial response (PR). Response evaluation criteria in solid tumors (RECIST) v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions that had a reduction in short axis to less than (\<) 10 millimeter (mm). Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30 percent (%) decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Any radiological assessments taken more than 30 days after the last dose of study therapy or after antineoplastic agents other than study treatments taken by the participants was excluded from the best overall response derivation. Confirmation of CR or PR was to be at least 4 weeks apart from the previous radiological assessment. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Steady State Maximum Concentration (Css,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | Part 1: pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D15; Part 2: pre-dose, 1, 2, 4, 6 hours post-dose on C1D15 | Css,max of PF-06873600 after multiple doses of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B and Part 2) was reported. Multiple-dose PK parameters were not calculated for the modified release selection cohort in Part 1C (ie, the group Part 1C PF-06873600 MR 20 IR 25 mg BID). |
| Time to Maximum Plasma Concentration at Steady State (Tss,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | Part 1: pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D15; Part 2: pre-dose, 1, 2, 4, 6 hours post-dose on C1D15 | Tss,max of PF-06873600 after multiple doses of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B and Part 2) was reported. Multiple-dose PK parameters were not calculated for the modified release selection cohort in Part 1C (ie, the group Part 1C PF-06873600 MR 20 IR 25 mg BID). |
| Steady State Minimum Plasma Concentration (Css,Min) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | Part 1: pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D15; Part 2: pre-dose, 1, 2, 4, 6 hours post-dose on C1D15 | Css,min of PF-06873600 after multiple doses of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B and Part 2) was reported. Multiple-dose PK parameters were not calculated for the modified release selection cohort in Part 1C (ie, the group Part 1C PF-06873600 MR 20 IR 25 mg BID). |
| Steady-State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCss,Tau) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D15 | AUCss,tau of PF-06873600 after multiple doses of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B) was reported. Multiple-dose PK parameters were not calculated for the modified release selection cohort in Part 1C (ie, the group Part 1C PF-06873600 MR 20 IR 25 mg BID). |
| Steady-State Apparent Oral Plasma Clearance (CLss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D15 | CLss/F of PF-06873600 after multiple doses of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B) was reported. Multiple-dose PK parameters were not calculated for the modified release selection cohort in Part 1C (ie, the group Part 1C PF-06873600 MR 20 IR 25 mg BID). |
| Maximum Observed Plasma Concentration (Cmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | Part 1: pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on Cycle 1 Day 1 (C1D1); Part 2: pre-dose, 1, 2, 4, 6 hours post-dose on C1D1 | The maximum observed concentration of PF-06873600 after single dose of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B and Part 2) was reported. The Cmax value was observed directly from data. |
| Accumulation Ratio Based on AUC (Rac) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D15 | Rac of PF-06873600 after multiple doses of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B) was reported. Multiple-dose PK parameters were not calculated for the modified release selection cohort in Part 1C (ie, the group Part 1C PF-06873600 MR 20 IR 25 mg BID). |
| Accumulation Ratio Based on Cmax (Observed) (Rac,Cmax) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 2 | Pre-dose, 1, 2, 4, 6 hours post-dose on C1D15 | Rac,cmax of PF-06873600 after multiple doses of study intervention when given as in combination with fulvestrant (Part 2) was reported. |
| Pharmacodynamic (PD) Biomarker Phospho-retinoblastoma Protein (pRb) in Tumor Tissue in Participants - Part 1 + Part 2 | Screening and Cycle 2 Day 1 | Level of the PD marker, pRb, was analyzed at 2 time points, at screening and at Cycle 2 Day 1. Percentage changes of pRb at Cycle 2 Day 1 from screening (baseline) were calculated. |
| PD Biomarker Ki67 in Tumor Tissue in Participants - Part 1 + Part 2 | Screening and Cycle 2 Day 1 | Level of the PD marker, Ki67, was analyzed at 2 time points, at screening and at Cycle 2 Day 1. Percent changes of pRb at Cycle 2 Day 1 from screening (baseline) were calculated. |
| Apparent Volume of Distribution at Steady State (Vss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D15 | Vss/F of PF-06873600 after multiple doses of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B) was reported. Multiple-dose PK parameters were not calculated for the modified release selection cohort in Part 1C (ie, the group Part 1C PF-06873600 MR 20 IR 25 mg BID). |
| Time to Reach Cmax at Steady State (Tmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | Part 1: pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D1; Part 2: pre-dose, 1, 2, 4, 6 hours post-dose on C1D1 | Tmax of PF-06873600 after single dose of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B and Part 2) was reported. |
| Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D1 | AUClast of PF-06873600 after single dose of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B) was reported. |
| Area Under the Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D1 | AUCinf of PF-06873600 after single dose of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B) was reported. |
| Apparent Clearance (CL/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D1 | CL/F of PF-06873600 after single dose of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B) was reported. |
| Apparent Volume of Distribution (Vz/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D1 | Vz/F of PF-06873600 after single dose of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B) was reported. |
| Terminal Half-life (t1/2) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D1 | t1/2 of PF-06873600 after single dose of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B) was reported. |
Countries
Bulgaria, Canada, Japan, Russia, Ukraine, United States
Participant flow
Recruitment details
Participants with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer (mBC), with locally recurrent/advanced or metastatic triple negative breast cancer (TNBC) or advanced platinum resistant ovarian/fallopian/peritoneal cancer, were recruited into this study. Two participants assigned to treatment but did not receive any study treatment were not included in any analysis.
Pre-assignment details
Primary outcome measures and secondary outcome measures analysis was final at primary completion date milestone and reported on the same milestone.
Participants by arm
| Arm | Count |
|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) Participants in Part 1A received PF-06873600 1 milligrams (mg) orally BID on a 28-day cycle from Day 1 to Day 28, until progression of disease, uncontrollable toxicity, a decision by the participant or investigator to discontinue treatment, or study termination. | 1 |
| Part 1A PF-06873600 2 mg BID Participants in Part 1A received PF-06873600 2 mg orally BID on a 28-day cycle from Day 1 to Day 28, until progression of disease, uncontrollable toxicity, a decision by the participant or investigator to discontinue treatment, or study termination. | 2 |
| Part 1A PF-06873600 5 mg BID Participants in Part 1A received PF-06873600 5 mg orally BID on a 28-day cycle from Day 1 to Day 28, until progression of disease, uncontrollable toxicity, a decision by the participant or investigator to discontinue treatment, or study termination. | 2 |
| Part 1A PF-06873600 10 mg BID Participants in Part 1A received PF-06873600 10 mg orally BID on a 28-day cycle from Day 1 to Day 28, until progression of disease, uncontrollable toxicity, a decision by the participant or investigator to discontinue treatment, or study termination. | 3 |
| Part 1A PF-06873600 25 mg BID Participants in Part 1A received PF-06873600 25 mg orally BID on a 28-day cycle from Day 1 to Day 28, until progression of disease, uncontrollable toxicity, a decision by the participant or investigator to discontinue treatment, or study termination. | 9 |
| Part 1A PF-06873600 25 mg BID Biomarker Participants in Part 1A, with pre and on-treatment tumor and skin biopsies collected, received PF-06873600 25 mg orally BID on a 28-day cycle from Day 1 to Day 28, until progression of disease, uncontrollable toxicity, a decision by the participant or investigator to discontinue treatment, or study termination. | 7 |
| Part 1A PF-06873600 35 mg BID Participants in Part 1A received PF-06873600 35 mg orally BID on a 28-day cycle from Day 1 to Day 28, until progression of disease, uncontrollable toxicity, a decision by the participant or investigator to discontinue treatment, or study termination. | 4 |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off Participants in Part 1A received PF-06873600 35 mg orally intermittent dosing 5 days on/2 days off on a 28-day cycle, until progression of disease, uncontrollable toxicity, a decision by the participant or investigator to discontinue treatment, or study termination. | 13 |
| Part 1A PF-06873600 50 mg BID Participants in Part 1A received PF-06873600 50 mg orally BID on a 28-day cycle from Day 1 to Day 28, until progression of disease, uncontrollable toxicity, a decision by the participant or investigator to discontinue treatment, or study termination. | 10 |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination Participants in Part 1B received PF-06873600 IR 25 mg orally BID on a 28-day cycle from Day 1 to Day 28 plus fulvestrant 500 mg intramuscularly on Day 1 and Day 15 of Cycle 1, Day 1 of Cycle 2, and monthly thereafter, until progression of disease, uncontrollable toxicity, a decision by the participant or investigator to discontinue treatment, or the study was terminated. | 9 |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination Participants in Part 1B received PF-06873600 IR 25 mg orally BID on a 28-day cycle from Day 1 to Day 28 plus letrozole 2.5 mg once daily as continuous daily dosing, until progression of disease, uncontrollable toxicity, a decision by the participant or investigator to discontinue treatment, or study termination. | 7 |
| Part 1C PF-06873600 Modified Release (MR) 20 mg IR 25 mg BID Participants in Part 1C received a single dose of PF-06873600 MR 20 mg orally during the lead-in period on Day -7 and Day -4, followed by IR 25 mg BID starting from Cycle 1 Day 1 orally BID on a 28-day cycle, until progression of disease, uncontrollable toxicity, a decision by the participant or investigator to discontinue treatment, or study termination. | 5 |
| Part 1C PF-06873600 MR 30 mg BID Long Release Participants in Part 1C received PF-06873600 MR 30 mg BID starting from Cycle 1 Day 1 orally BID on a 28-day cycle, until progression of disease, uncontrollable toxicity, a decision by the participant or investigator to discontinue treatment, or study termination. | 6 |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination Participants in Part 2A had received cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) treatment before received PF-06873600 IR 25 mg orally BID on a 28-day cycle from Day 1 to Day 28 plus fulvestrant 500 mg intramuscularly on Day 1 and Day 15 of Cycle 1, Day 1 of Cycle 2, and monthly thereafter, until progression of disease, uncontrollable toxicity, a decision by the participant or investigator to discontinue treatment, or study termination. | 45 |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination Participants in Part 2C who were naïve to CDK4/6i received PF-06873600 IR 25 mg orally BID on a 28-day cycle from Day 1 to Day 28 plus fulvestrant 500 mg intramuscularly on Day 1 and Day 15 of Cycle 1, Day 1 of Cycle 2, and monthly thereafter, until progression of disease, uncontrollable toxicity, a decision by the participant or investigator to discontinue treatment, or study termination. | 28 |
| Total | 151 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 | FG006 | FG007 | FG008 | FG009 | FG010 | FG011 | FG012 | FG013 | FG014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Follow-Up | Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 0 | 0 | 2 | 0 | 0 |
| Follow-Up | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up | Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Follow-Up | Withdrawal by Subject | 1 | 2 | 2 | 3 | 5 | 1 | 2 | 6 | 5 | 2 | 3 | 5 | 2 | 0 | 0 |
| Fulvestrant. Treatment | Adverse Event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Fulvestrant. Treatment | Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Fulvestrant. Treatment | Global deterioration of health status | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 0 |
| Fulvestrant. Treatment | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Fulvestrant. Treatment | Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 |
| Fulvestrant. Treatment | Physician Decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 2 |
| Fulvestrant. Treatment | Progressive disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 30 | 8 |
| Fulvestrant. Treatment | Refused further treatment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Fulvestrant. Treatment | Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 9 |
| Fulvestrant. Treatment | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 2 |
| Letrozole Treatment | Global deterioration of health status | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Letrozole Treatment | Physician Decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Letrozole Treatment | Progressive disease | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 |
| Long-term Follow-up | Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 |
| Long-term Follow-up | Global deterioration of health status | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Long-term Follow-up | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Long-term Follow-up | Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Long-term Follow-up | Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 32 | 19 |
| Long-term Follow-up | Withdrawal by Subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 3 |
| PF-06873600 Treatment | Adverse Event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 1 | 3 | 2 |
| PF-06873600 Treatment | Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 |
| PF-06873600 Treatment | Global deterioration of health status | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 2 | 1 | 1 | 2 | 0 | 0 | 3 | 0 |
| PF-06873600 Treatment | Lost to Follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| PF-06873600 Treatment | Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 3 |
| PF-06873600 Treatment | Physician Decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 4 | 1 |
| PF-06873600 Treatment | Progressive disease | 1 | 1 | 1 | 1 | 6 | 7 | 3 | 7 | 3 | 5 | 4 | 3 | 4 | 28 | 8 |
| PF-06873600 Treatment | Refused further treatment | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| PF-06873600 Treatment | Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 9 |
| PF-06873600 Treatment | Withdrawal by Subject | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 1 | 3 | 2 | 0 | 2 | 1 | 1 | 2 |
Baseline characteristics
| Characteristic | Total | Part 1A PF-06873600 2 mg BID | Part 1A PF-06873600 5 mg BID | Part 1A PF-06873600 10 mg BID | Part 1A PF-06873600 25 mg BID | Part 1A PF-06873600 1 mg Twice a Day (BID) | Part 1A PF-06873600 25 mg BID Biomarker | Part 1A PF-06873600 35 mg BID | Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Part 1A PF-06873600 50 mg BID | Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Part 1C PF-06873600 Modified Release (MR) 20 mg IR 25 mg BID | Part 1C PF-06873600 MR 30 mg BID Long Release | Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 43 Participants | 0 Participants | 1 Participants | 2 Participants | 2 Participants | 0 Participants | 1 Participants | 1 Participants | 2 Participants | 3 Participants | 3 Participants | 1 Participants | 3 Participants | 2 Participants | 11 Participants | 11 Participants |
| Age, Categorical Between 18 and 65 years | 108 Participants | 2 Participants | 1 Participants | 1 Participants | 7 Participants | 1 Participants | 6 Participants | 3 Participants | 11 Participants | 7 Participants | 6 Participants | 6 Participants | 2 Participants | 4 Participants | 34 Participants | 17 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 12 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 2 Participants | 2 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 5 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 130 Participants | 2 Participants | 2 Participants | 3 Participants | 8 Participants | 1 Participants | 6 Participants | 2 Participants | 10 Participants | 9 Participants | 7 Participants | 6 Participants | 4 Participants | 6 Participants | 37 Participants | 27 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 9 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 2 Participants | 0 Participants | 1 Participants | 0 Participants | 3 Participants | 1 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 22 Participants | 0 Participants | 1 Participants | 0 Participants | 3 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 2 Participants | 5 Participants | 8 Participants |
| Race (NIH/OMB) Black or African American | 10 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants | 4 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 10 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants | 2 Participants | 1 Participants | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 4 Participants | 0 Participants |
| Race (NIH/OMB) White | 108 Participants | 2 Participants | 1 Participants | 3 Participants | 4 Participants | 1 Participants | 6 Participants | 3 Participants | 8 Participants | 8 Participants | 9 Participants | 4 Participants | 5 Participants | 2 Participants | 32 Participants | 20 Participants |
| Sex: Female, Male Female | 151 Participants | 2 Participants | 2 Participants | 3 Participants | 9 Participants | 1 Participants | 7 Participants | 4 Participants | 13 Participants | 10 Participants | 9 Participants | 7 Participants | 5 Participants | 6 Participants | 45 Participants | 28 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk | EG006 affected / at risk | EG007 affected / at risk | EG008 affected / at risk | EG009 affected / at risk | EG010 affected / at risk | EG011 affected / at risk | EG012 affected / at risk | EG013 affected / at risk | EG014 affected / at risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 1 | 0 / 2 | 0 / 2 | 0 / 3 | 1 / 9 | 0 / 7 | 0 / 4 | 1 / 13 | 3 / 10 | 1 / 9 | 0 / 7 | 0 / 5 | 3 / 6 | 6 / 45 | 4 / 28 |
| other Total, other adverse events | 1 / 1 | 2 / 2 | 2 / 2 | 3 / 3 | 9 / 9 | 6 / 7 | 4 / 4 | 13 / 13 | 10 / 10 | 9 / 9 | 7 / 7 | 5 / 5 | 6 / 6 | 45 / 45 | 25 / 28 |
| serious Total, serious adverse events | 0 / 1 | 1 / 2 | 0 / 2 | 0 / 3 | 2 / 9 | 0 / 7 | 1 / 4 | 4 / 13 | 6 / 10 | 1 / 9 | 2 / 7 | 0 / 5 | 3 / 6 | 9 / 45 | 5 / 28 |
Outcome results
Primary
Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2
An AE was defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occurred after participants' signed informed consent has been obtained. An SAE was an AE resulting in any of the following outcomes: was fatal or life-threatening; resulted in persistent or significant disability/incapacity; constituted a congenital anomaly/birth defect; was medically significant; required inpatient hospitalization or prolongation of existing hospitalization. Treatment Related AEs were treatment emergent AEs with cause categorized by the investigator as related to study treatment.
Time frame: Day 1 up to 28 days after the last dose of study intervention, up to approximately 24 months
Population: The safety analysis set included all enrolled participants who received at least 1 dose of study intervention.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality SAEs | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related AEs | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related SAEs | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality AEs | 1 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality SAEs | 1 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related SAEs | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality AEs | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related AEs | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related AEs | 1 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality AEs | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related SAEs | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality SAEs | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality SAEs | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related AEs | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related SAEs | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality AEs | 3 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related SAEs | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related AEs | 8 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality SAEs | 2 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality AEs | 9 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality SAEs | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related AEs | 6 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality AEs | 6 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related SAEs | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related AEs | 4 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality SAEs | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related SAEs | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality AEs | 4 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related SAEs | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality AEs | 13 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality SAEs | 4 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related AEs | 13 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality SAEs | 6 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related AEs | 10 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality AEs | 10 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related SAEs | 3 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality AEs | 9 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality SAEs | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related AEs | 8 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related SAEs | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related AEs | 7 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related SAEs | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality AEs | 7 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality SAEs | 2 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality SAEs | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related AEs | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related SAEs | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality AEs | 5 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality AEs | 6 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related SAEs | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related AEs | 5 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality SAEs | 3 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality AEs | 45 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality SAEs | 9 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related AEs | 45 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related SAEs | 5 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality SAEs | 5 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related SAEs | 2 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | Treatment-related AEs | 24 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) - Part 1 + Part 2 | All-causality AEs | 25 Participants |
Primary
Number of Participants With Dose Limiting Toxicities (DLTs) - Part 1
DLT was defined as any of the following adverse events (AEs) occurring in the first cycle of treatment (28 days) which were attributable to one, the other, or both agents in the combination: Hematologic - grade(G) 4 neutropenia lasting \>7 days; Febrile neutropenia defined as an absolute neutrophil count (ANC) \<1.0 \* 10\^9/L with a single temperature of \>38.3°C, or a sustained temperature of ≥38°C, for more than 1 hour; G≥3 neutropenia with associated infection; G3 thrombocytopenia with clinically significant bleeding as indicated by ≥ G2 bleeding; G4 thrombocytopenia. Nonhematologic: Confirmed case of Drug Induced Liver Injury (DILI) (Hy's Law); G≥3 AEs that were clinically significant.
Time frame: Cycle 1 (within 28 days after the first dose of study intervention)
Population: Analysis population consisted of all enrolled participants who received at least 1 dose of study intervention and who did not have major treatment deviations during the first cycle (ie, evaluable for the maximum tolerated dose \[MTD\]).
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Dose Limiting Toxicities (DLTs) - Part 1 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Dose Limiting Toxicities (DLTs) - Part 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Dose Limiting Toxicities (DLTs) - Part 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Dose Limiting Toxicities (DLTs) - Part 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Dose Limiting Toxicities (DLTs) - Part 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Dose Limiting Toxicities (DLTs) - Part 1 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Dose Limiting Toxicities (DLTs) - Part 1 | 2 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Dose Limiting Toxicities (DLTs) - Part 1 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Dose Limiting Toxicities (DLTs) - Part 1 | 4 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Dose Limiting Toxicities (DLTs) - Part 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Dose Limiting Toxicities (DLTs) - Part 1 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Dose Limiting Toxicities (DLTs) - Part 1 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Dose Limiting Toxicities (DLTs) - Part 1 | 0 Participants |
Primary
Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2
ECG pre-defined categories for QTc interval adjusted according to Fridericia formula (QTcF) (msec) included: 450 \<= max. \<=480, 481 \<= max. \<=500, max \>=501; QTcF CFB: 30 \< max \<=60, max \>60; for PR and QRS: PR (msec): max \>=300; PR increase from baseline: Baseline \>200 and max. \>=25% increase, Baseline \<=200 and max. \>=50% increase; QRS (msec): max \>=200; QRS (msec) increase from baseline: Baseline \>100 and max. \>=25% increase, Baseline \<=100 and max. \>=50% increase. Categories, with at least 1 participant having ECG abnormality in any of the reporting arms, were reported in this outcome measure.
Time frame: Day 1 up to 28 days after the last dose of study intervention, up to approximately 24 months
Population: The safety analysis set included all enrolled participants who received at least 1 dose of study intervention. Only participants with evaluable ECG results were included in the analysis.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): value >=501 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval not otherwise specified (NOS) (msec) baseline >200 and percent change >=25% | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline <=100 and change from baseline >=50% | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval NOS (msec) baseline <=200 and percent change >=50% | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): change from baseline >60 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 481 <= value <=500 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 30 <= change from baseline <=60 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline >100 and change from baseline >=25% | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 450 <= value <=480 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): change from baseline >60 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 30 <= change from baseline <=60 | 1 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 481 <= value <=500 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval not otherwise specified (NOS) (msec) baseline >200 and percent change >=25% | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline <=100 and change from baseline >=50% | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval NOS (msec) baseline <=200 and percent change >=50% | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 450 <= value <=480 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): value >=501 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline >100 and change from baseline >=25% | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline >100 and change from baseline >=25% | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 450 <= value <=480 | 1 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline <=100 and change from baseline >=50% | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 481 <= value <=500 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval not otherwise specified (NOS) (msec) baseline >200 and percent change >=25% | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 30 <= change from baseline <=60 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): change from baseline >60 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): value >=501 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval NOS (msec) baseline <=200 and percent change >=50% | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline <=100 and change from baseline >=50% | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): change from baseline >60 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval NOS (msec) baseline <=200 and percent change >=50% | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 30 <= change from baseline <=60 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline >100 and change from baseline >=25% | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval not otherwise specified (NOS) (msec) baseline >200 and percent change >=25% | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): value >=501 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 450 <= value <=480 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 481 <= value <=500 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval NOS (msec) baseline <=200 and percent change >=50% | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): change from baseline >60 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): value >=501 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 30 <= change from baseline <=60 | 2 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline <=100 and change from baseline >=50% | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 450 <= value <=480 | 2 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval not otherwise specified (NOS) (msec) baseline >200 and percent change >=25% | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 481 <= value <=500 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline >100 and change from baseline >=25% | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline >100 and change from baseline >=25% | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval not otherwise specified (NOS) (msec) baseline >200 and percent change >=25% | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): value >=501 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval NOS (msec) baseline <=200 and percent change >=50% | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): change from baseline >60 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 450 <= value <=480 | 2 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline <=100 and change from baseline >=50% | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 481 <= value <=500 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 30 <= change from baseline <=60 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): value >=501 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval NOS (msec) baseline <=200 and percent change >=50% | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 30 <= change from baseline <=60 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): change from baseline >60 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 450 <= value <=480 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline >100 and change from baseline >=25% | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval not otherwise specified (NOS) (msec) baseline >200 and percent change >=25% | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline <=100 and change from baseline >=50% | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 481 <= value <=500 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 450 <= value <=480 | 6 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval not otherwise specified (NOS) (msec) baseline >200 and percent change >=25% | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval NOS (msec) baseline <=200 and percent change >=50% | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline >100 and change from baseline >=25% | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline <=100 and change from baseline >=50% | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 481 <= value <=500 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): value >=501 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 30 <= change from baseline <=60 | 2 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): change from baseline >60 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline <=100 and change from baseline >=50% | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline >100 and change from baseline >=25% | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 481 <= value <=500 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval NOS (msec) baseline <=200 and percent change >=50% | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval not otherwise specified (NOS) (msec) baseline >200 and percent change >=25% | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): change from baseline >60 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 450 <= value <=480 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 30 <= change from baseline <=60 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): value >=501 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): value >=501 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval NOS (msec) baseline <=200 and percent change >=50% | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): change from baseline >60 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline <=100 and change from baseline >=50% | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 450 <= value <=480 | 3 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 481 <= value <=500 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval not otherwise specified (NOS) (msec) baseline >200 and percent change >=25% | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 30 <= change from baseline <=60 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline >100 and change from baseline >=25% | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 30 <= change from baseline <=60 | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): change from baseline >60 | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline <=100 and change from baseline >=50% | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 450 <= value <=480 | 4 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline >100 and change from baseline >=25% | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): value >=501 | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 481 <= value <=500 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval NOS (msec) baseline <=200 and percent change >=50% | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval not otherwise specified (NOS) (msec) baseline >200 and percent change >=25% | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 481 <= value <=500 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline <=100 and change from baseline >=50% | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): change from baseline >60 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline >100 and change from baseline >=25% | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): value >=501 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval NOS (msec) baseline <=200 and percent change >=50% | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 30 <= change from baseline <=60 | 1 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval not otherwise specified (NOS) (msec) baseline >200 and percent change >=25% | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 450 <= value <=480 | 3 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 30 <= change from baseline <=60 | 2 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): value >=501 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 450 <= value <=480 | 2 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 481 <= value <=500 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval not otherwise specified (NOS) (msec) baseline >200 and percent change >=25% | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline >100 and change from baseline >=25% | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): change from baseline >60 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval NOS (msec) baseline <=200 and percent change >=50% | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline <=100 and change from baseline >=50% | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval not otherwise specified (NOS) (msec) baseline >200 and percent change >=25% | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): value >=501 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): change from baseline >60 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline >100 and change from baseline >=25% | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 30 <= change from baseline <=60 | 9 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 450 <= value <=480 | 14 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 481 <= value <=500 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline <=100 and change from baseline >=50% | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval NOS (msec) baseline <=200 and percent change >=50% | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval not otherwise specified (NOS) (msec) baseline >200 and percent change >=25% | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): change from baseline >60 | 2 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 30 <= change from baseline <=60 | 5 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 450 <= value <=480 | 5 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline >100 and change from baseline >=25% | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QRS interval not otherwise specified (NOS) (msec): baseline <=100 and change from baseline >=50% | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): value >=501 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | QTcF NOS (msec): 481 <= value <=500 | 2 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Electrocardiogram (ECG) Changes Meeting Pre-Defined Categorization - Part 1 + Part 2 | PR interval NOS (msec) baseline <=200 and percent change >=50% | 1 Participants |
Primary
Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2
Pre-defined criteria included: 1) systolic blood pressure (SBP) (mm Hg) minimum (min) value \<90; 2) SBP change from baseline (CFB) (mm Hg) maximum (max) decrease \>=30 or max increase \>=30; 3) diastolic blood pressure (DBP) (mm Hg) min \<50; 4) DBP CFB (mm Hg) max decrease \>=20 or max increase \>=20; 5) supine heart rate (HR) beats per minute (bpm) min \<40 or max \>120.
Time frame: Day 1 up to 28 days after the last dose of study intervention, up to approximately 24 months
Population: The safety analysis set included all enrolled participants who received at least 1 dose of study intervention. For each vital sign measurement, only participants with evaluable vital sign results were included in the analysis.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 decrease | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 increase | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP (mm Hg) <90 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP (mm Hg) <50 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 increase | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 decrease | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) <40 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) >120 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 increase | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 decrease | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) >120 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP (mm Hg) <50 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) <40 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 increase | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP (mm Hg) <90 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 decrease | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 decrease | 1 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) <40 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP (mm Hg) <90 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 increase | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP (mm Hg) <50 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 decrease | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 increase | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) >120 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP (mm Hg) <90 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) >120 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 decrease | 1 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 increase | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP (mm Hg) <50 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 decrease | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 increase | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) <40 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 decrease | 3 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 increase | 1 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) >120 | 2 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) <40 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 decrease | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 increase | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP (mm Hg) <50 | 4 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP (mm Hg) <90 | 2 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 decrease | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 decrease | 1 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) >120 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 increase | 1 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP (mm Hg) <50 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 increase | 2 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP (mm Hg) <90 | 1 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) <40 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP (mm Hg) <50 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 decrease | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 increase | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) >120 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) <40 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 decrease | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP (mm Hg) <90 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 increase | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP (mm Hg) <90 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 increase | 3 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 decrease | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP (mm Hg) <50 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 increase | 3 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 decrease | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) <40 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) >120 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) <40 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 decrease | 3 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP (mm Hg) <90 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) >120 | 2 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 increase | 2 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP (mm Hg) <50 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 decrease | 3 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 increase | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP (mm Hg) <50 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP (mm Hg) <90 | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 decrease | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 increase | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) <40 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) >120 | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 decrease | 3 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 increase | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 increase | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP (mm Hg) <90 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP (mm Hg) <50 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 decrease | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 decrease | 2 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) >120 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 increase | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) <40 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP (mm Hg) <50 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP (mm Hg) <90 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 increase | 1 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 decrease | 1 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 decrease | 1 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) <40 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 increase | 1 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) >120 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 increase | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) <40 | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP (mm Hg) <90 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP (mm Hg) <50 | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 decrease | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 decrease | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 increase | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) >120 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 decrease | 13 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 increase | 2 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP (mm Hg) <90 | 3 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 decrease | 10 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP (mm Hg) <50 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) >120 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) <40 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 increase | 5 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 increase | 2 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP (mm Hg) <50 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) <40 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | Heart rate (bpm) >120 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP CFB (mm Hg) >= 30 decrease | 2 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 increase | 4 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | SBP (mm Hg) <90 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Post-Baseline Vital Sign Abnormalities Meeting Pre-Defined Categorization - Part 1 + Part 2 | DBP CFB (mm Hg) >=20 decrease | 4 Participants |
Primary
Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2
Severity was graded as NCI CTCAE version 4.03:Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE.
Time frame: Day 1 up to 28 days after the last dose of study intervention, up to approximately 24 months
Population: The safety analysis set included all enrolled participants who received at least 1 dose of study intervention. For each laboratory parameter, only participants with evaluable laboratory results were included in the analysis.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 2 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 0 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 0 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 2 | NA Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 2 | NA Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 1 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 0 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 2 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 4 | NA Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 0 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 2 | NA Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 2 | 1 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 0 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 0 | 1 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 1 | 1 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 4 | NA Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 1 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 2 | NA Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 4 | NA Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 2 | NA Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 1 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 2 | NA Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 1 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 0 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 0 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 1 | 1 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 0 | 1 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 0 | 3 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 2 | NA Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 0 | 1 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 0 | 3 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 0 | 3 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 1 | 2 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 2 | 1 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 0 | 3 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 0 | 3 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 1 | 2 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 1 | 1 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 0 | 3 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 0 | 3 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 0 | 1 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 1 | 2 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 0 | 3 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 0 | 3 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 0 | 3 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 2 | NA Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 2 | 1 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 0 | 3 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 4 | NA Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 0 | 5 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 0 | 4 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 3 | 1 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 0 | 8 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 0 | 8 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 0 | 7 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 1 | 1 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 0 | 5 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 2 | 2 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 1 | 4 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 1 | 2 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 0 | 9 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 2 | NA Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 1 | 3 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 1 | 5 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 0 | 6 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 0 | 8 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 1 | 2 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 2 | 2 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 2 | NA Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 0 | 9 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 2 | 1 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 0 | 9 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 0 | 7 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 1 | 1 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 1 | 2 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 0 | 6 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 4 | NA Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 1 | 3 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 0 | 8 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 1 | 1 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 0 | 9 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 0 | 5 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 2 | 1 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 0 | 5 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 1 | 4 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 0 | 5 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 0 | 9 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 1 | 4 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 0 | 5 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 0 | 6 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 1 | 2 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 0 | 4 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 0 | 6 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 0 | 7 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 0 | 5 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 1 | 3 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 0 | 3 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 2 | 1 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 0 | 6 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 2 | 2 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 0 | 5 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 1 | 4 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 2 | NA Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 0 | 6 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 0 | 7 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 0 | 7 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 4 | NA Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 0 | 3 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 0 | 4 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 1 | 4 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 2 | 1 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 1 | 3 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 1 | 2 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 0 | 5 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 0 | 7 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 0 | 7 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 2 | NA Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 0 | 7 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 2 | 1 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 0 | 4 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 1 | 2 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 2 | 1 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 1 | 2 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 0 | 3 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 0 | 3 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 2 | NA Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 0 | 3 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 1 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 2 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 1 | 3 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 0 | 3 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 0 | 3 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 1 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 0 | 4 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 0 | 3 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 0 | 4 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 1 | 2 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 0 | 4 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 0 | 4 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 2 | NA Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 0 | 4 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 1 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 0 | 4 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 4 | NA Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 0 | 4 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 0 | 4 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 2 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 0 | 3 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 2 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 0 | 4 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 2 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 2 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 0 | 12 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 0 | 12 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 0 | 10 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 0 | 11 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 3 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 1 | 2 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 0 | 12 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 0 | 13 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 2 | 3 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 1 | 2 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 3 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 1 | 3 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 1 | 3 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 2 | 2 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 1 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 1 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 3 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 0 | 9 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 0 | 13 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 0 | 12 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 0 | 7 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 0 | 9 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 0 | 9 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 0 | 11 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 0 | 3 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 2 | NA Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 1 | 5 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 0 | 10 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 1 | 3 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 0 | 9 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 1 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 4 | NA Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 0 | 13 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 0 | 12 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 1 | 2 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 2 | 2 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 1 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 2 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 3 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 2 | NA Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 3 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 0 | 10 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 3 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 1 | 8 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 3 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 0 | 7 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 0 | 8 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 3 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 0 | 3 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 1 | 5 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 1 | 2 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 2 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 0 | 7 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 1 | 3 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 2 | NA Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 2 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 0 | 3 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 1 | 7 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 0 | 8 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 0 | 8 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 1 | 4 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 0 | 5 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 3 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 0 | 7 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 0 | 10 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 1 | 4 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 4 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 4 | NA Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 0 | 6 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 0 | 6 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 0 | 8 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 1 | 3 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 0 | 8 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 1 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 2 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 2 | 2 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 0 | 7 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 2 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 3 | 2 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 0 | 8 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 1 | 2 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 0 | 9 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 0 | 9 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 2 | NA Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 1 | 2 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 1 | 3 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 0 | 9 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 4 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 2 | 2 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 1 | 2 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 0 | 7 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 2 | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 0 | 6 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 1 | 3 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 0 | 9 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 0 | 9 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 0 | 8 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 2 | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 1 | 6 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 1 | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 2 | NA Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 2 | 2 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 0 | 7 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 3 | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 0 | 7 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 3 | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 0 | 6 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 0 | 8 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 1 | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 0 | 5 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 0 | 8 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 0 | 8 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 0 | 3 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 1 | 4 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 0 | 7 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 0 | 7 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 0 | 9 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 1 | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 4 | NA Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 1 | 3 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 4 | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 0 | 9 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 1 | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 1 | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 2 | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 0 | 6 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 1 | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 0 | 8 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 1 | 2 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 2 | NA Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 2 | NA Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 1 | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 0 | 5 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 0 | 3 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 1 | 5 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 0 | 4 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 0 | 7 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 0 | 6 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 1 | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 0 | 6 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 0 | 2 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 1 | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 1 | 5 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 0 | 6 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 1 | 3 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 1 | 2 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 0 | 5 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 0 | 6 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 0 | 2 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 0 | 7 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 2 | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 0 | 6 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 4 | NA Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 2 | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 2 | NA Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 1 | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 0 | 7 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 1 | 4 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 0 | 7 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 3 | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 1 | 3 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 0 | 7 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 0 | 5 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 1 | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 0 | 5 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 1 | 2 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 0 | 4 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 2 | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 2 | 1 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 1 | 3 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 2 | NA Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 1 | 1 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 2 | 1 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 1 | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 0 | 3 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 0 | 2 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 2 | NA Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 0 | 2 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 1 | 2 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 1 | 2 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 1 | 2 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 0 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 4 | NA Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 0 | 2 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 0 | 4 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 1 | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 2 | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 1 | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 4 | NA Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 0 | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 0 | 4 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 1 | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 0 | 6 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 1 | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 0 | 6 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 1 | 4 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 2 | NA Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 0 | 6 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 0 | 3 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 1 | 2 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 0 | 2 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 2 | NA Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 1 | 3 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 1 | 2 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 0 | 6 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 0 | 4 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 2 | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 0 | 6 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 0 | 6 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 0 | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 4 | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 2 | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 0 | 4 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 1 | 3 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 1 | 2 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 0 | 4 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 0 | 6 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 1 | 5 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 2 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 4 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 2 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 2 | 2 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 3 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 1 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 3 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 4 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 4 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 0 | 36 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 1 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 2 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 1 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 2 | 3 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 3 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 2 | 11 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 3 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 2 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 0 | 44 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 0 | 38 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 3 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 0 | 24 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 1 | 22 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 3 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 3 | 2 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 2 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 1 | 7 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 3 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 4 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 1 | 5 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 2 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 1 | 18 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 4 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 0 | 42 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 0 | 38 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 0 | 35 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 4 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 3 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 0 | 41 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 0 | 23 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 3 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 2 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 4 | NA Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 2 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 1 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 0 | 31 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 4 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 0 | 44 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 0 | 21 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 1 | 3 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 3 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 4 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 4 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 1 | 3 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 3 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 2 | NA Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 4 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 1 | 5 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 4 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 3 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 1 | 13 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 3 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 3 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 2 | NA Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 3 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 4 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 1 | 2 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 0 | 39 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 1 | 5 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 0 | 40 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 0 | 33 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 0 | 42 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 2 | 3 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 2 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 1 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 3 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 0 | 45 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 3 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 1 | 20 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 1 | 7 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 2 | 2 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 4 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 2 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 3 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 4 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 2 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 4 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 0 | 41 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 2 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 1 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 4 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 2 | 2 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 0 | 42 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 1 | 4 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 0 | 20 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 1 | 5 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 0 | 15 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 1 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 1 | 9 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 2 | NA Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 1 | 3 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 3 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 3 | 4 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 2 | 2 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 2 | NA Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 3 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 2 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 0 | 24 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 3 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 0 | 22 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 3 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 2 | 3 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 3 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 2 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 1 | 6 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 2 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 1 | 4 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 3 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 2 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 2 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 0 | 15 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 3 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 0 | 22 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 1 | 2 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 3 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 0 | 19 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 1 | 3 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 0 | 19 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 0 | 18 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 1 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 2 | 4 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 0 | 7 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 3 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 2 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 1 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 1 | 3 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 3 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 0 | 16 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lipase increased | Grade 2 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 0 | 13 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypercalcemia | Grade 2 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 1 | 6 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 1 | 8 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 3 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 0 | 14 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 2 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypermagnesemia | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alanine aminotransferase increased | Grade 2 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Creatinine increased | Grade 1 | 17 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 0 | 16 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 0 | 20 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 4 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypocalcemia | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 1 | 2 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 3 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 1 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 0 | 23 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Blood bilirubin increased | Grade 3 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypernatremia | Grade 2 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 4 | NA Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 3 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Serum amylase increased | Grade 3 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoglycemia | Grade 2 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypomagnesemia | Grade 1 | 10 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypokalemia | Grade 3 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 1 | 5 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 3 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Aspartate aminotransferase increased | Grade 3 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypoalbuminemia | Grade 2 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 1 | 8 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyponatremia | Grade 0 | 20 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperkalemia | Grade 0 | 23 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Alkaline phosphatase increased | Grade 2 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hyperglycemia | Grade 0 | 12 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Chemistry Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hypophosphatemia | Grade 4 | 0 Participants |
Primary
Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2
Severity was graded as NCI CTCAE version 4.03:Grade 1: asymptomatic or mild symptoms, clinical or diagnostic observations only, intervention not indicated; Grade 2: moderate, minimal, local or noninvasive intervention indicated, limiting age-appropriate instrumental activities of daily life (ADL); Grade 3: severe or medically significant but not immediately life-threatening, hospitalization or prolongation of existing hospitalization indicated, disabling, limiting self-care ADL; Grade 4: life-threatening consequence, urgent intervention indicated; Grade 5: death related to AE.
Time frame: Day 1 up to 28 days after the last dose of study intervention, up to approximately 24 months
Population: The safety analysis set included all enrolled participants who received at least 1 dose of study intervention. For each laboratory parameter, only participants with evaluable laboratory results were included in the analysis.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 1 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 0 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 2 | NA Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 4 | NA Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 1 | NA Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 1 | NA Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 4 | NA Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 4 | NA Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 4 | NA Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 2 | NA Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 4 | NA Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 1 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 1 | NA Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 4 | NA Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 1 | NA Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 0 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 2 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 4 | NA Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 1 | NA Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 4 | NA Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 4 | NA Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 2 | NA Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 1 | NA Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 2 | 1 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 0 | 2 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 0 | 1 Participants |
| Part 1A PF-06873600 5 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 0 | 3 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 2 | 1 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 4 | NA Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 1 | 2 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 0 | 2 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 0 | 3 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 4 | NA Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 0 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 1 | 3 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 0 | 3 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 0 | 3 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 0 | 3 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 1 | NA Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 2 | NA Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 3 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 4 | NA Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 1 | NA Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 10 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 0 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 0 | 9 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 1 | 1 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 3 | 2 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 0 | 4 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 2 | 2 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 0 | 4 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 1 | NA Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 0 | 7 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 1 | 2 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 4 | NA Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 3 | 2 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 0 | 7 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 3 | 1 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 0 | 6 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 0 | 3 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 1 | 2 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 4 | NA Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 2 | NA Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 2 | 1 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 3 | 1 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 2 | 4 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 2 | 5 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 1 | NA Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 2 | 4 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 4 | NA Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 0 | 9 Participants |
| Part 1A PF-06873600 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 0 | 9 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 1 | 2 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 0 | 2 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 0 | 7 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 1 | 3 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 2 | 2 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 2 | 2 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 0 | 7 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 4 | NA Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 0 | 5 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 0 | 7 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 1 | 3 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 0 | 7 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 2 | 3 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 1 | NA Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 0 | 7 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 2 | NA Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 2 | 2 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 4 | NA Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 1 | NA Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 3 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 0 | 5 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 3 | 2 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 25 mg BID Biomarker | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 4 | NA Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 3 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 0 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 0 | 3 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 4 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 4 | 2 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 4 | NA Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 4 | NA Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 3 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 4 | NA Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 0 | 3 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 2 | NA Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 0 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 0 | 4 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 2 | 2 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 4 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 2 | 2 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 3 | 3 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 0 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 1 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 0 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 1 | NA Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 1 | NA Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 2 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 0 | 1 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 0 | 4 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 0 | 4 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 3 | 2 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 1 | 2 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 0 | 3 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 0 | 5 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 0 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 0 | 13 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 2 | 4 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 4 | NA Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 3 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 2 | 6 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 1 | NA Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 1 | 2 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 1 | 7 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 2 | NA Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 2 | 5 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 1 | 5 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 0 | 13 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 0 | 9 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 3 | 2 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 1 | 3 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 3 | 2 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 3 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 0 | 8 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 4 | NA Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 2 | 6 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 1 | NA Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 0 | 6 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 0 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 0 | 13 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 3 | 1 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 1 | 3 Participants |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 4 | NA Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 4 | NA Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 0 | 10 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 0 | 6 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 0 | 6 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 1 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 2 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 4 | NA Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 0 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 1 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 2 | 5 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 3 | 4 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 0 | 10 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 1 | NA Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 2 | NA Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 4 | NA Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 0 | 2 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 1 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 2 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 3 | 6 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 4 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 0 | 10 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 1 | NA Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 4 | NA Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 0 | 4 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 2 | 2 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 3 | 1 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 4 | 3 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 0 | 5 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 1 | 3 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 2 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 3 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 4 | 2 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 0 | 3 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 1 | 0 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 2 | 3 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 3 | 2 Participants |
| Part 1A PF-06873600 50 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 4 | 2 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 0 | 9 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 0 | 3 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 4 | NA Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 0 | 7 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 1 | NA Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 0 | 9 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 4 | NA Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 3 | 3 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 4 | NA Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 0 | 9 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 2 | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 2 | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 0 | 5 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 4 | NA Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 1 | 4 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 0 | 7 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 4 | NA Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 0 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 2 | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 1 | 1 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 0 | 2 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 0 | 7 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 1 | NA Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 3 | 2 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 2 | 3 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 1 | 4 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 4 | NA Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 2 | 5 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 1 | 3 Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 2 | NA Participants |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 1 | 2 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 1 | 3 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 0 | 6 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 4 | NA Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 0 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 2 | 4 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 2 | NA Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 0 | 7 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 1 | NA Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 0 | 7 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 4 | NA Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 3 | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 4 | NA Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 0 | 7 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 0 | 2 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 0 | 2 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 3 | 2 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 2 | 5 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 4 | NA Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 2 | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 2 | 6 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 0 | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 1 | NA Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 4 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 4 | NA Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 3 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 4 | NA Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 0 | 4 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 2 | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 1 | 3 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 1 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 1 | 1 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 2 | 0 Participants |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 4 | NA Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 0 | 4 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 0 | 4 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 4 | NA Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 0 | 3 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 1 | 1 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 1 | 4 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 2 | 3 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 3 | 1 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 4 | NA Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 0 | 2 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 2 | NA Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 0 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 4 | NA Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 4 | NA Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 1 | 2 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 2 | 2 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 2 | 1 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 0 | 2 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 4 | NA Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 0 | 5 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 0 | 2 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 1 | NA Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 1 | NA Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 1 | 2 Participants |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 1 | NA Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 1 | 3 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 3 | 2 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 1 | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 2 | 4 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 4 | NA Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 2 | NA Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 2 | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 3 | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 4 | NA Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 0 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 3 | 2 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 0 | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 1 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 4 | NA Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 4 | NA Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 1 | 3 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 0 | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 1 | NA Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 0 | 4 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 4 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 4 | NA Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 0 | 6 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 0 | 6 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 4 | NA Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 0 | 6 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 3 | 1 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 2 | 4 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 0 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 0 | 6 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 3 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 0 | 6 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 2 | 0 Participants |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 1 | 2 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 0 | 33 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 0 | 14 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 0 | 45 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 4 | NA Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 1 | NA Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 3 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 2 | NA Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 2 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 1 | NA Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 3 | 7 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 3 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 0 | 45 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 4 | NA Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 4 | NA Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 3 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 0 | 16 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 2 | 3 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 1 | 6 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 3 | 7 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 2 | 19 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 4 | NA Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 2 | 7 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 1 | 10 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 3 | 9 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 0 | 9 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 4 | NA Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 4 | 7 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 3 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 0 | 28 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 2 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 1 | 14 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 1 | 3 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 2 | 2 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 3 | 1 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 1 | 4 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 0 | 29 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 4 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 4 | NA Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 0 | 11 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 3 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 1 | 8 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 2 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 1 | 0 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 2 | 16 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 0 | 45 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 4 | 3 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 3 | 4 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 2 | 21 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 1 | 6 Participants |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 0 | 13 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 1 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 1 | 8 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 2 | NA Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 1 | 7 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 1 | 4 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 2 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 0 | 17 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 3 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 4 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 1 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Activated partial thromboplastin time prolonged | Grade 4 | NA Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 3 | 4 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 0 | 5 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 1 | 12 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 2 | 9 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 2 | 5 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 3 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 2 | 8 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 1 | 4 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 4 | NA Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Anemia | Grade 3 | 4 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 0 | 26 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 1 | NA Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 2 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Neutrophil count decreased | Grade 0 | 8 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 3 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 4 | NA Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 4 | NA Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 4 | NA Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 3 | 3 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 0 | 26 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 0 | 26 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 3 | 2 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 2 | 5 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count decreased | Grade 0 | 15 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 3 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Leukocytosis | Grade 1 | NA Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 0 | 7 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 4 | NA Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 3 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Lymphocyte count increased | Grade 2 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 4 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 0 | 9 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 3 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | White blood cell decreased | Grade 4 | 1 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Hemoglobin increased | Grade 2 | 0 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | International normalized ratio (INR) increased | Grade 1 | 3 Participants |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Number of Participants With Worst Post-Baseline Hematology Results Based on Common Terminology Criteria for Adverse Events (CTCAE) Grade: Part 1 + Part 2 | Platelet count decreased | Grade 2 | 0 Participants |
Primary
Overall Response Rate (ORR): Part 2
ORR: percentage of participants with confirmed complete response (CR) or partial response (PR). Response evaluation criteria in solid tumors (RECIST) v1.1: a) CR = disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions that had a reduction in short axis to less than (\<) 10 millimeter (mm). Disappearance of all non-target lesions. In addition, all lymph nodes assigned a non-target lesion must be non-pathological in size (\<10 mm short axis) and b) PR = at least a 30 percent (%) decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters. Any radiological assessments taken more than 30 days after the last dose of study therapy or after antineoplastic agents other than study treatments taken by the participants was excluded from the best overall response derivation. Confirmation of CR or PR was to be at least 4 weeks apart from the previous radiological assessment.
Time frame: From the start of the treatment until disease/clinical progression or death or early study discontinuation, whichever happened earlier (approximately up to 24 months)
Population: For Part 2: the response evaluable population included all participants who received at least 1 dose of study treatment and had baseline disease and at least 1 post baseline disease assessment.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Overall Response Rate (ORR): Part 2 | 6.7 Percentage of participants |
| Part 1A PF-06873600 2 mg BID | Overall Response Rate (ORR): Part 2 | 22.7 Percentage of participants |
Secondary
Accumulation Ratio Based on AUC (Rac) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1
Rac of PF-06873600 after multiple doses of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B) was reported. Multiple-dose PK parameters were not calculated for the modified release selection cohort in Part 1C (ie, the group Part 1C PF-06873600 MR 20 IR 25 mg BID).
Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D15
Population: The PK parameter analysis population included all enrolled participants treated who had sufficient information to estimate at least 1 of the PK parameters of interest. Geometric Coefficient of Variation was not presented for parameters with participants with evaluable data \<3 at that time point.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Accumulation Ratio Based on AUC (Rac) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 1.210 Ratio | — |
| Part 1A PF-06873600 2 mg BID | Accumulation Ratio Based on AUC (Rac) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 1.160 Ratio | — |
| Part 1A PF-06873600 5 mg BID | Accumulation Ratio Based on AUC (Rac) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 1.53 Ratio | — |
| Part 1A PF-06873600 10 mg BID | Accumulation Ratio Based on AUC (Rac) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 0.7263 Ratio | Geometric Coefficient of Variation 28 |
| Part 1A PF-06873600 25 mg BID | Accumulation Ratio Based on AUC (Rac) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 1.045 Ratio | Geometric Coefficient of Variation 17 |
| Part 1A PF-06873600 25 mg BID Biomarker | Accumulation Ratio Based on AUC (Rac) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 1.254 Ratio | Geometric Coefficient of Variation 49 |
| Part 1A PF-06873600 35 mg BID | Accumulation Ratio Based on AUC (Rac) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 0.822 Ratio | — |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Accumulation Ratio Based on AUC (Rac) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 0.8893 Ratio | Geometric Coefficient of Variation 32 |
| Part 1A PF-06873600 50 mg BID | Accumulation Ratio Based on AUC (Rac) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 1.260 Ratio | Geometric Coefficient of Variation 25 |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Accumulation Ratio Based on AUC (Rac) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 1.191 Ratio | Geometric Coefficient of Variation 29 |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Accumulation Ratio Based on AUC (Rac) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 1.268 Ratio | Geometric Coefficient of Variation 35 |
Secondary
Accumulation Ratio Based on Cmax (Observed) (Rac,Cmax) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 2
Rac,cmax of PF-06873600 after multiple doses of study intervention when given as in combination with fulvestrant (Part 2) was reported.
Time frame: Pre-dose, 1, 2, 4, 6 hours post-dose on C1D15
Population: The PK parameter analysis population included all enrolled participants treated who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Accumulation Ratio Based on Cmax (Observed) (Rac,Cmax) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 2 | 1.161 Ratio | Geometric Coefficient of Variation 78 |
| Part 1A PF-06873600 2 mg BID | Accumulation Ratio Based on Cmax (Observed) (Rac,Cmax) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 2 | 1.381 Ratio | Geometric Coefficient of Variation 34 |
Secondary
Apparent Clearance (CL/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1
CL/F of PF-06873600 after single dose of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B) was reported.
Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D1
Population: The PK parameter analysis population included all enrolled participants treated who had sufficient information to estimate at least 1 of the PK parameters of interest. Geometric Coefficient of Variation was not presented for parameters with participants with evaluable data \<3 at that time point. For groups where 2 participants were evaluable for the PK parameter, exact data were presented, instead of the geometric mean (geometric CV).
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Apparent Clearance (CL/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 47.6 Liter per hour | — |
| Part 1A PF-06873600 2 mg BID | Apparent Clearance (CL/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 44.2 Liter per hour | — |
| Part 1A PF-06873600 5 mg BID | Apparent Clearance (CL/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 49.7 Liter per hour | — |
| Part 1A PF-06873600 10 mg BID | Apparent Clearance (CL/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 15.43 Liter per hour | Geometric Coefficient of Variation 60 |
| Part 1A PF-06873600 25 mg BID | Apparent Clearance (CL/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 16.78 Liter per hour | Geometric Coefficient of Variation 20 |
| Part 1A PF-06873600 25 mg BID Biomarker | Apparent Clearance (CL/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 28.04 Liter per hour | Geometric Coefficient of Variation 73 |
| Part 1A PF-06873600 35 mg BID | Apparent Clearance (CL/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 10.3 Liter per hour | Geometric Coefficient of Variation 17.4 |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Apparent Clearance (CL/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 21.70 Liter per hour | Geometric Coefficient of Variation 48 |
| Part 1A PF-06873600 50 mg BID | Apparent Clearance (CL/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 26.63 Liter per hour | Geometric Coefficient of Variation 41 |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Apparent Clearance (CL/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 28.26 Liter per hour | Geometric Coefficient of Variation 34 |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Apparent Clearance (CL/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 21.87 Liter per hour | Geometric Coefficient of Variation 50 |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Apparent Clearance (CL/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 42.14 Liter per hour | Geometric Coefficient of Variation 17 |
Secondary
Apparent Volume of Distribution at Steady State (Vss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1
Vss/F of PF-06873600 after multiple doses of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B) was reported. Multiple-dose PK parameters were not calculated for the modified release selection cohort in Part 1C (ie, the group Part 1C PF-06873600 MR 20 IR 25 mg BID).
Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D15
Population: The PK parameter analysis population included all enrolled participants treated who had sufficient information to estimate at least 1 of the PK parameters of interest. Geometric Coefficient of Variation was not presented for parameters with participants with evaluable data \<3 at that time point. For groups where 2 participants were evaluable for the PK parameter, exact data were presented, instead of the geometric mean (geometric CV).
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1A PF-06873600 2 mg BID | Apparent Volume of Distribution at Steady State (Vss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 53.3 Liter | Geometric Coefficient of Variation 98.4 |
| Part 1A PF-06873600 5 mg BID | Apparent Volume of Distribution at Steady State (Vss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 124 Liter | — |
| Part 1A PF-06873600 10 mg BID | Apparent Volume of Distribution at Steady State (Vss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 72.17 Liter | Geometric Coefficient of Variation 19 |
| Part 1A PF-06873600 25 mg BID | Apparent Volume of Distribution at Steady State (Vss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 57.62 Liter | Geometric Coefficient of Variation 29 |
| Part 1A PF-06873600 25 mg BID Biomarker | Apparent Volume of Distribution at Steady State (Vss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 99.62 Liter | Geometric Coefficient of Variation 35 |
| Part 1A PF-06873600 35 mg BID | Apparent Volume of Distribution at Steady State (Vss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 70.8 Liter | — |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Apparent Volume of Distribution at Steady State (Vss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 99.03 Liter | Geometric Coefficient of Variation 48 |
| Part 1A PF-06873600 50 mg BID | Apparent Volume of Distribution at Steady State (Vss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 75.41 Liter | Geometric Coefficient of Variation 17 |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Apparent Volume of Distribution at Steady State (Vss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 75.71 Liter | Geometric Coefficient of Variation 32 |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Apparent Volume of Distribution at Steady State (Vss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 80.33 Liter | Geometric Coefficient of Variation 27 |
Secondary
Apparent Volume of Distribution (Vz/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1
Vz/F of PF-06873600 after single dose of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B) was reported.
Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D1
Population: The PK parameter analysis population included all enrolled participants treated who had sufficient information to estimate at least 1 of the PK parameters of interest. Geometric Coefficient of Variation was not presented for parameters with participants with evaluable data \<3 at that time point. For groups where 2 participants were evaluable for the PK parameter, exact data were presented, instead of the geometric mean (geometric CV).
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Apparent Volume of Distribution (Vz/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 111 Liter | — |
| Part 1A PF-06873600 2 mg BID | Apparent Volume of Distribution (Vz/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 116 Liter | — |
| Part 1A PF-06873600 5 mg BID | Apparent Volume of Distribution (Vz/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 141 Liter | — |
| Part 1A PF-06873600 10 mg BID | Apparent Volume of Distribution (Vz/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 55.32 Liter | Geometric Coefficient of Variation 28 |
| Part 1A PF-06873600 25 mg BID | Apparent Volume of Distribution (Vz/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 61.33 Liter | Geometric Coefficient of Variation 20 |
| Part 1A PF-06873600 25 mg BID Biomarker | Apparent Volume of Distribution (Vz/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 97.32 Liter | Geometric Coefficient of Variation 56 |
| Part 1A PF-06873600 35 mg BID | Apparent Volume of Distribution (Vz/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 55.5 Liter | Geometric Coefficient of Variation 60 |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Apparent Volume of Distribution (Vz/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 86.06 Liter | Geometric Coefficient of Variation 37 |
| Part 1A PF-06873600 50 mg BID | Apparent Volume of Distribution (Vz/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 79.74 Liter | Geometric Coefficient of Variation 15 |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Apparent Volume of Distribution (Vz/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 83.54 Liter | Geometric Coefficient of Variation 17 |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Apparent Volume of Distribution (Vz/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 72.18 Liter | Geometric Coefficient of Variation 37 |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Apparent Volume of Distribution (Vz/F) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 132.2 Liter | Geometric Coefficient of Variation 52 |
Secondary
Area Under the Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1
AUCinf of PF-06873600 after single dose of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B) was reported.
Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D1
Population: The PK parameter analysis population included all enrolled participants treated who had sufficient information to estimate at least 1 of the PK parameters of interest. Geometric Coefficient of Variation was not presented for parameters with participants with evaluable data \<3 at that time point. For groups where 2 participants were evaluable for the PK parameter, exact data were presented, instead of the geometric mean (geometric CV).
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Area Under the Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 21.0 Hour*nanogram per milliliter | — |
| Part 1A PF-06873600 2 mg BID | Area Under the Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 45.2 Hour*nanogram per milliliter | — |
| Part 1A PF-06873600 5 mg BID | Area Under the Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 101 Hour*nanogram per milliliter | — |
| Part 1A PF-06873600 10 mg BID | Area Under the Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 648.4 Hour*nanogram per milliliter | Geometric Coefficient of Variation 60 |
| Part 1A PF-06873600 25 mg BID | Area Under the Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 1492 Hour*nanogram per milliliter | Geometric Coefficient of Variation 20 |
| Part 1A PF-06873600 25 mg BID Biomarker | Area Under the Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 892.6 Hour*nanogram per milliliter | Geometric Coefficient of Variation 73 |
| Part 1A PF-06873600 35 mg BID | Area Under the Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 2010 Hour*nanogram per milliliter | Geometric Coefficient of Variation 3400 |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Area Under the Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 1614 Hour*nanogram per milliliter | Geometric Coefficient of Variation 48 |
| Part 1A PF-06873600 50 mg BID | Area Under the Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 1875 Hour*nanogram per milliliter | Geometric Coefficient of Variation 41 |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Area Under the Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 884.3 Hour*nanogram per milliliter | Geometric Coefficient of Variation 34 |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Area Under the Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 1142 Hour*nanogram per milliliter | Geometric Coefficient of Variation 50 |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Area Under the Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 593.3 Hour*nanogram per milliliter | Geometric Coefficient of Variation 17 |
Secondary
Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1
AUClast of PF-06873600 after single dose of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B) was reported.
Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D1
Population: The PK parameter analysis population included all enrolled participants treated who had sufficient information to estimate at least 1 of the PK parameters of interest. Geometric Coefficient of Variation was not presented for parameters with participants with evaluable data \<3 at that time point. For groups where 2 participants were evaluable for the PK parameter, exact data were presented, instead of the geometric mean (geometric CV).
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 18.3 Hour*nanogram per milliliter | — |
| Part 1A PF-06873600 2 mg BID | Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 39.2 Hour*nanogram per milliliter | Geometric Coefficient of Variation 58.3 |
| Part 1A PF-06873600 5 mg BID | Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 96.6 Hour*nanogram per milliliter | Geometric Coefficient of Variation 442 |
| Part 1A PF-06873600 10 mg BID | Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 599.4 Hour*nanogram per milliliter | Geometric Coefficient of Variation 53 |
| Part 1A PF-06873600 25 mg BID | Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 1295 Hour*nanogram per milliliter | Geometric Coefficient of Variation 25 |
| Part 1A PF-06873600 25 mg BID Biomarker | Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 787.9 Hour*nanogram per milliliter | Geometric Coefficient of Variation 59 |
| Part 1A PF-06873600 35 mg BID | Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 2510 Hour*nanogram per milliliter | Geometric Coefficient of Variation 25 |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 1395 Hour*nanogram per milliliter | Geometric Coefficient of Variation 38 |
| Part 1A PF-06873600 50 mg BID | Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 1976 Hour*nanogram per milliliter | Geometric Coefficient of Variation 49 |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 1034 Hour*nanogram per milliliter | Geometric Coefficient of Variation 43 |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 1040 Hour*nanogram per milliliter | Geometric Coefficient of Variation 46 |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 596.8 Hour*nanogram per milliliter | Geometric Coefficient of Variation 33 |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 192.0 Hour*nanogram per milliliter | Geometric Coefficient of Variation 201 |
Secondary
Maximum Observed Plasma Concentration (Cmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2
The maximum observed concentration of PF-06873600 after single dose of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B and Part 2) was reported. The Cmax value was observed directly from data.
Time frame: Part 1: pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on Cycle 1 Day 1 (C1D1); Part 2: pre-dose, 1, 2, 4, 6 hours post-dose on C1D1
Population: The PK parameter analysis population included all enrolled participants treated who had sufficient information to estimate at least 1 of the PK parameters of interest. Geometric Coefficient of Variation was not presented for parameters with participants with evaluable data \<3 at that time point. For groups where 2 participants were evaluable for the PK parameter, exact data were presented, instead of the geometric mean (geometric coefficient of variation \[CV\]).
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Maximum Observed Plasma Concentration (Cmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 5.39 Nanogram per milliliter | — |
| Part 1A PF-06873600 2 mg BID | Maximum Observed Plasma Concentration (Cmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 22.1 Nanogram per milliliter | Geometric Coefficient of Variation 31.9 |
| Part 1A PF-06873600 5 mg BID | Maximum Observed Plasma Concentration (Cmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 29.1 Nanogram per milliliter | Geometric Coefficient of Variation 90.8 |
| Part 1A PF-06873600 10 mg BID | Maximum Observed Plasma Concentration (Cmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 164.1 Nanogram per milliliter | Geometric Coefficient of Variation 37 |
| Part 1A PF-06873600 25 mg BID | Maximum Observed Plasma Concentration (Cmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 243.5 Nanogram per milliliter | Geometric Coefficient of Variation 47 |
| Part 1A PF-06873600 25 mg BID Biomarker | Maximum Observed Plasma Concentration (Cmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 202.6 Nanogram per milliliter | Geometric Coefficient of Variation 47 |
| Part 1A PF-06873600 35 mg BID | Maximum Observed Plasma Concentration (Cmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 388.1 Nanogram per milliliter | Geometric Coefficient of Variation 9 |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Maximum Observed Plasma Concentration (Cmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 276.4 Nanogram per milliliter | Geometric Coefficient of Variation 42 |
| Part 1A PF-06873600 50 mg BID | Maximum Observed Plasma Concentration (Cmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 393.8 Nanogram per milliliter | Geometric Coefficient of Variation 42 |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Maximum Observed Plasma Concentration (Cmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 225.4 Nanogram per milliliter | Geometric Coefficient of Variation 28 |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Maximum Observed Plasma Concentration (Cmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 228.5 Nanogram per milliliter | Geometric Coefficient of Variation 32 |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Maximum Observed Plasma Concentration (Cmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 121.8 Nanogram per milliliter | Geometric Coefficient of Variation 54 |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Maximum Observed Plasma Concentration (Cmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 43.51 Nanogram per milliliter | Geometric Coefficient of Variation 121 |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Maximum Observed Plasma Concentration (Cmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 224.9 Nanogram per milliliter | Geometric Coefficient of Variation 43 |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Maximum Observed Plasma Concentration (Cmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 181.4 Nanogram per milliliter | Geometric Coefficient of Variation 41 |
Secondary
PD Biomarker Ki67 in Tumor Tissue in Participants - Part 1 + Part 2
Level of the PD marker, Ki67, was analyzed at 2 time points, at screening and at Cycle 2 Day 1. Percent changes of pRb at Cycle 2 Day 1 from screening (baseline) were calculated.
Time frame: Screening and Cycle 2 Day 1
Population: The biomarker analysis population was all enrolled participants with PD biomarkers evaluated at pre-and/post dose.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A PF-06873600 25 mg BID | PD Biomarker Ki67 in Tumor Tissue in Participants - Part 1 + Part 2 | -63.64 Percentage of change |
| Part 1A PF-06873600 25 mg BID Biomarker | PD Biomarker Ki67 in Tumor Tissue in Participants - Part 1 + Part 2 | -6.67 Percentage of change |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | PD Biomarker Ki67 in Tumor Tissue in Participants - Part 1 + Part 2 | -90.00 Percentage of change |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | PD Biomarker Ki67 in Tumor Tissue in Participants - Part 1 + Part 2 | -33.33 Percentage of change |
Secondary
Pharmacodynamic (PD) Biomarker Phospho-retinoblastoma Protein (pRb) in Tumor Tissue in Participants - Part 1 + Part 2
Level of the PD marker, pRb, was analyzed at 2 time points, at screening and at Cycle 2 Day 1. Percentage changes of pRb at Cycle 2 Day 1 from screening (baseline) were calculated.
Time frame: Screening and Cycle 2 Day 1
Population: The biomarker analysis population was all enrolled participants with PD biomarkers evaluated at pre-and/post dose.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A PF-06873600 25 mg BID | Pharmacodynamic (PD) Biomarker Phospho-retinoblastoma Protein (pRb) in Tumor Tissue in Participants - Part 1 + Part 2 | -84.44 Percentage of change |
| Part 1A PF-06873600 25 mg BID Biomarker | Pharmacodynamic (PD) Biomarker Phospho-retinoblastoma Protein (pRb) in Tumor Tissue in Participants - Part 1 + Part 2 | -11.11 Percentage of change |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Pharmacodynamic (PD) Biomarker Phospho-retinoblastoma Protein (pRb) in Tumor Tissue in Participants - Part 1 + Part 2 | -77.50 Percentage of change |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Pharmacodynamic (PD) Biomarker Phospho-retinoblastoma Protein (pRb) in Tumor Tissue in Participants - Part 1 + Part 2 | -30.43 Percentage of change |
Secondary
Steady-State Apparent Oral Plasma Clearance (CLss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1
CLss/F of PF-06873600 after multiple doses of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B) was reported. Multiple-dose PK parameters were not calculated for the modified release selection cohort in Part 1C (ie, the group Part 1C PF-06873600 MR 20 IR 25 mg BID).
Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D15
Population: The PK parameter analysis population included all enrolled participants treated who had sufficient information to estimate at least 1 of the PK parameters of interest. Geometric Coefficient of Variation was not presented for parameters with participants with evaluable data \<3 at that time point. For groups where 2 participants were evaluable for the PK parameter, exact data were presented, instead of the geometric mean (geometric CV).
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Steady-State Apparent Oral Plasma Clearance (CLss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 39.5 Liter per hour | — |
| Part 1A PF-06873600 2 mg BID | Steady-State Apparent Oral Plasma Clearance (CLss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 23.0 Liter per hour | Geometric Coefficient of Variation 38.9 |
| Part 1A PF-06873600 5 mg BID | Steady-State Apparent Oral Plasma Clearance (CLss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 10.4 Liter per hour | Geometric Coefficient of Variation 33.2 |
| Part 1A PF-06873600 10 mg BID | Steady-State Apparent Oral Plasma Clearance (CLss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 22.28 Liter per hour | Geometric Coefficient of Variation 24 |
| Part 1A PF-06873600 25 mg BID | Steady-State Apparent Oral Plasma Clearance (CLss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 14.78 Liter per hour | Geometric Coefficient of Variation 34 |
| Part 1A PF-06873600 25 mg BID Biomarker | Steady-State Apparent Oral Plasma Clearance (CLss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 24.76 Liter per hour | Geometric Coefficient of Variation 40 |
| Part 1A PF-06873600 35 mg BID | Steady-State Apparent Oral Plasma Clearance (CLss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 14.8 Liter per hour | Geometric Coefficient of Variation 17 |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Steady-State Apparent Oral Plasma Clearance (CLss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 25.54 Liter per hour | Geometric Coefficient of Variation 39 |
| Part 1A PF-06873600 50 mg BID | Steady-State Apparent Oral Plasma Clearance (CLss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 21.99 Liter per hour | Geometric Coefficient of Variation 44 |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Steady-State Apparent Oral Plasma Clearance (CLss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 20.35 Liter per hour | Geometric Coefficient of Variation 41 |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Steady-State Apparent Oral Plasma Clearance (CLss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 19.63 Liter per hour | Geometric Coefficient of Variation 49 |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Steady-State Apparent Oral Plasma Clearance (CLss/F) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 47.08 Liter per hour | Geometric Coefficient of Variation 59 |
Secondary
Steady-State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCss,Tau) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1
AUCss,tau of PF-06873600 after multiple doses of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B) was reported. Multiple-dose PK parameters were not calculated for the modified release selection cohort in Part 1C (ie, the group Part 1C PF-06873600 MR 20 IR 25 mg BID).
Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D15
Population: The PK parameter analysis population included all enrolled participants treated who had sufficient information to estimate at least 1 of the PK parameters of interest. Geometric Coefficient of Variation was not presented for parameters with participants with evaluable data \<3 at that time point. For groups where 2 participants were evaluable for the PK parameter, exact data were presented, instead of the geometric mean (geometric CV).
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Steady-State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCss,Tau) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 25.3 Hour*nanogram per milliliter | — |
| Part 1A PF-06873600 2 mg BID | Steady-State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCss,Tau) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 51.4 Hour*nanogram per milliliter | Geometric Coefficient of Variation 86.9 |
| Part 1A PF-06873600 5 mg BID | Steady-State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCss,Tau) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 150 Hour*nanogram per milliliter | Geometric Coefficient of Variation 483 |
| Part 1A PF-06873600 10 mg BID | Steady-State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCss,Tau) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 448.8 Hour*nanogram per milliliter | Geometric Coefficient of Variation 25 |
| Part 1A PF-06873600 25 mg BID | Steady-State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCss,Tau) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 1695 Hour*nanogram per milliliter | Geometric Coefficient of Variation 34 |
| Part 1A PF-06873600 25 mg BID Biomarker | Steady-State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCss,Tau) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 1010 Hour*nanogram per milliliter | Geometric Coefficient of Variation 40 |
| Part 1A PF-06873600 35 mg BID | Steady-State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCss,Tau) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 2060 Hour*nanogram per milliliter | Geometric Coefficient of Variation 2360 |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Steady-State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCss,Tau) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 1372 Hour*nanogram per milliliter | Geometric Coefficient of Variation 39 |
| Part 1A PF-06873600 50 mg BID | Steady-State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCss,Tau) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 1607 Hour*nanogram per milliliter | Geometric Coefficient of Variation 34 |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Steady-State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCss,Tau) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 1229 Hour*nanogram per milliliter | Geometric Coefficient of Variation 41 |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Steady-State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCss,Tau) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 1273 Hour*nanogram per milliliter | Geometric Coefficient of Variation 50 |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Steady-State Area Under the Plasma Concentration Versus Time Curve Within One Dose Interval (AUCss,Tau) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 | 636.8 Hour*nanogram per milliliter | Geometric Coefficient of Variation 59 |
Secondary
Steady State Maximum Concentration (Css,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2
Css,max of PF-06873600 after multiple doses of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B and Part 2) was reported. Multiple-dose PK parameters were not calculated for the modified release selection cohort in Part 1C (ie, the group Part 1C PF-06873600 MR 20 IR 25 mg BID).
Time frame: Part 1: pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D15; Part 2: pre-dose, 1, 2, 4, 6 hours post-dose on C1D15
Population: The PK parameter analysis population included all enrolled participants treated who had sufficient information to estimate at least 1 of the PK parameters of interest. Geometric Coefficient of Variation was not presented for parameters with participants with evaluable data \<3 at that time point. For groups where 2 participants were evaluable for the PK parameter, exact data were presented, instead of the geometric mean (geometric CV).
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Steady State Maximum Concentration (Css,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 10.9 Nanogram per milliliter | — |
| Part 1A PF-06873600 2 mg BID | Steady State Maximum Concentration (Css,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 18.2 Nanogram per milliliter | Geometric Coefficient of Variation 45.4 |
| Part 1A PF-06873600 5 mg BID | Steady State Maximum Concentration (Css,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 46.3 Nanogram per milliliter | Geometric Coefficient of Variation 126 |
| Part 1A PF-06873600 10 mg BID | Steady State Maximum Concentration (Css,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 124.3 Nanogram per milliliter | Geometric Coefficient of Variation 29 |
| Part 1A PF-06873600 25 mg BID | Steady State Maximum Concentration (Css,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 382.4 Nanogram per milliliter | Geometric Coefficient of Variation 33 |
| Part 1A PF-06873600 25 mg BID Biomarker | Steady State Maximum Concentration (Css,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 246.4 Nanogram per milliliter | Geometric Coefficient of Variation 40 |
| Part 1A PF-06873600 35 mg BID | Steady State Maximum Concentration (Css,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 362 Nanogram per milliliter | Geometric Coefficient of Variation 399 |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Steady State Maximum Concentration (Css,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 290.2 Nanogram per milliliter | Geometric Coefficient of Variation 29 |
| Part 1A PF-06873600 50 mg BID | Steady State Maximum Concentration (Css,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 335.2 Nanogram per milliliter | Geometric Coefficient of Variation 22 |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Steady State Maximum Concentration (Css,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 305.0 Nanogram per milliliter | Geometric Coefficient of Variation 35 |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Steady State Maximum Concentration (Css,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 276.5 Nanogram per milliliter | Geometric Coefficient of Variation 31 |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Steady State Maximum Concentration (Css,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 82.11 Nanogram per milliliter | Geometric Coefficient of Variation 72 |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Steady State Maximum Concentration (Css,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 273.5 Nanogram per milliliter | Geometric Coefficient of Variation 35 |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Steady State Maximum Concentration (Css,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 250.5 Nanogram per milliliter | Geometric Coefficient of Variation 44 |
Secondary
Steady State Minimum Plasma Concentration (Css,Min) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2
Css,min of PF-06873600 after multiple doses of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B and Part 2) was reported. Multiple-dose PK parameters were not calculated for the modified release selection cohort in Part 1C (ie, the group Part 1C PF-06873600 MR 20 IR 25 mg BID).
Time frame: Part 1: pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D15; Part 2: pre-dose, 1, 2, 4, 6 hours post-dose on C1D15
Population: The PK parameter analysis population included all enrolled participants treated who had sufficient information to estimate at least 1 of the PK parameters of interest. Geometric Coefficient of Variation was not presented for parameters with participants with evaluable data \<3 at that time point. For groups where 2 participants were evaluable for the PK parameter, exact data were presented, instead of the geometric mean (geometric CV).
| Arm | Measure | Value (GEOMETRIC_MEAN) | Dispersion |
|---|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Steady State Minimum Plasma Concentration (Css,Min) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 0.0000 Nanogram per milliliter | — |
| Part 1A PF-06873600 2 mg BID | Steady State Minimum Plasma Concentration (Css,Min) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 0.000 Nanogram per milliliter | Geometric Coefficient of Variation 0 |
| Part 1A PF-06873600 5 mg BID | Steady State Minimum Plasma Concentration (Css,Min) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 1.19 Nanogram per milliliter | Geometric Coefficient of Variation 23.6 |
| Part 1A PF-06873600 10 mg BID | Steady State Minimum Plasma Concentration (Css,Min) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 5.499 Nanogram per milliliter | Geometric Coefficient of Variation 5 |
| Part 1A PF-06873600 25 mg BID | Steady State Minimum Plasma Concentration (Css,Min) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 37.63 Nanogram per milliliter | Geometric Coefficient of Variation 112 |
| Part 1A PF-06873600 25 mg BID Biomarker | Steady State Minimum Plasma Concentration (Css,Min) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 21.28 Nanogram per milliliter | Geometric Coefficient of Variation 130 |
| Part 1A PF-06873600 35 mg BID | Steady State Minimum Plasma Concentration (Css,Min) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 52.1 Nanogram per milliliter | Geometric Coefficient of Variation 80.4 |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Steady State Minimum Plasma Concentration (Css,Min) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 25.56 Nanogram per milliliter | Geometric Coefficient of Variation 8 |
| Part 1A PF-06873600 50 mg BID | Steady State Minimum Plasma Concentration (Css,Min) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 25.63 Nanogram per milliliter | Geometric Coefficient of Variation 101 |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Steady State Minimum Plasma Concentration (Css,Min) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 21.25 Nanogram per milliliter | Geometric Coefficient of Variation 106 |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Steady State Minimum Plasma Concentration (Css,Min) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 13.33 Nanogram per milliliter | Geometric Coefficient of Variation 204 |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Steady State Minimum Plasma Concentration (Css,Min) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 45.78 Nanogram per milliliter | Geometric Coefficient of Variation 49 |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Steady State Minimum Plasma Concentration (Css,Min) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 23.67 Nanogram per milliliter | Geometric Coefficient of Variation 156 |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Steady State Minimum Plasma Concentration (Css,Min) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 19.16 Nanogram per milliliter | Geometric Coefficient of Variation 131 |
Secondary
Terminal Half-life (t1/2) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1
t1/2 of PF-06873600 after single dose of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B) was reported.
Time frame: Pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D1
Population: The PK parameter analysis population included all enrolled participants treated who had sufficient information to estimate at least 1 of the PK parameters of interest. Standard deviation was not presented for parameters with participants with evaluable data \<3 at that time point. For groups where 2 participants were evaluable for the PK parameter, exact data were presented, instead of the mean (standard deviation).
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Terminal Half-life (t1/2) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 1.61 Hour | — |
| Part 1A PF-06873600 2 mg BID | Terminal Half-life (t1/2) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 1.82 Hour | — |
| Part 1A PF-06873600 5 mg BID | Terminal Half-life (t1/2) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 1.96 Hour | — |
| Part 1A PF-06873600 10 mg BID | Terminal Half-life (t1/2) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 2.567 Hour | Standard Deviation 0.82033 |
| Part 1A PF-06873600 25 mg BID | Terminal Half-life (t1/2) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 2.540 Hour | Standard Deviation 0.14394 |
| Part 1A PF-06873600 25 mg BID Biomarker | Terminal Half-life (t1/2) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 2.446 Hour | Standard Deviation 0.54574 |
| Part 1A PF-06873600 35 mg BID | Terminal Half-life (t1/2) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 2.39 Hour | Standard Deviation 3.74 |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Terminal Half-life (t1/2) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 2.809 Hour | Standard Deviation 0.59669 |
| Part 1A PF-06873600 50 mg BID | Terminal Half-life (t1/2) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 2.163 Hour | Standard Deviation 0.74732 |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Terminal Half-life (t1/2) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 2.128 Hour | Standard Deviation 0.73966 |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Terminal Half-life (t1/2) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 2.428 Hour | Standard Deviation 0.87316 |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Terminal Half-life (t1/2) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 | 2.250 Hour | Standard Deviation 0.7735 |
Secondary
Time to Maximum Plasma Concentration at Steady State (Tss,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2
Tss,max of PF-06873600 after multiple doses of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B and Part 2) was reported. Multiple-dose PK parameters were not calculated for the modified release selection cohort in Part 1C (ie, the group Part 1C PF-06873600 MR 20 IR 25 mg BID).
Time frame: Part 1: pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D15; Part 2: pre-dose, 1, 2, 4, 6 hours post-dose on C1D15
Population: The PK parameter analysis population included all enrolled participants treated who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Time to Maximum Plasma Concentration at Steady State (Tss,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 1.00 Hour |
| Part 1A PF-06873600 2 mg BID | Time to Maximum Plasma Concentration at Steady State (Tss,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 1.25 Hour |
| Part 1A PF-06873600 5 mg BID | Time to Maximum Plasma Concentration at Steady State (Tss,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 1.20 Hour |
| Part 1A PF-06873600 10 mg BID | Time to Maximum Plasma Concentration at Steady State (Tss,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 2.00 Hour |
| Part 1A PF-06873600 25 mg BID | Time to Maximum Plasma Concentration at Steady State (Tss,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 1.95 Hour |
| Part 1A PF-06873600 25 mg BID Biomarker | Time to Maximum Plasma Concentration at Steady State (Tss,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 1.92 Hour |
| Part 1A PF-06873600 35 mg BID | Time to Maximum Plasma Concentration at Steady State (Tss,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 2.01 Hour |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Time to Maximum Plasma Concentration at Steady State (Tss,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 2.23 Hour |
| Part 1A PF-06873600 50 mg BID | Time to Maximum Plasma Concentration at Steady State (Tss,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 1.98 Hour |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Time to Maximum Plasma Concentration at Steady State (Tss,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 1.88 Hour |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Time to Maximum Plasma Concentration at Steady State (Tss,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 2.08 Hour |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Time to Maximum Plasma Concentration at Steady State (Tss,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 2.99 Hour |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Time to Maximum Plasma Concentration at Steady State (Tss,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 1.95 Hour |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Time to Maximum Plasma Concentration at Steady State (Tss,Max) of PF-06873600 Following Multiple Doses of Study Intervention on Cycle 1 Day 15 - Part 1 + Part 2 | 1.97 Hour |
Secondary
Time to Reach Cmax at Steady State (Tmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2
Tmax of PF-06873600 after single dose of study intervention when given as a single agent (Part 1A and Part 1C), in combination with letrozole, and in combination with fulvestrant (Part 1B and Part 2) was reported.
Time frame: Part 1: pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, 12 hours post-dose on C1D1; Part 2: pre-dose, 1, 2, 4, 6 hours post-dose on C1D1
Population: The PK parameter analysis population included all enrolled participants treated who had sufficient information to estimate at least 1 of the PK parameters of interest.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Part 1A PF-06873600 1 mg Twice a Day (BID) | Time to Reach Cmax at Steady State (Tmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 2.17 Hour |
| Part 1A PF-06873600 2 mg BID | Time to Reach Cmax at Steady State (Tmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 1.25 Hour |
| Part 1A PF-06873600 5 mg BID | Time to Reach Cmax at Steady State (Tmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 2.02 Hour |
| Part 1A PF-06873600 10 mg BID | Time to Reach Cmax at Steady State (Tmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 0.983 Hour |
| Part 1A PF-06873600 25 mg BID | Time to Reach Cmax at Steady State (Tmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 2.17 Hour |
| Part 1A PF-06873600 25 mg BID Biomarker | Time to Reach Cmax at Steady State (Tmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 1.90 Hour |
| Part 1A PF-06873600 35 mg BID | Time to Reach Cmax at Steady State (Tmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 3.64 Hour |
| Part 1A PF-06873600 35 mg Intermittent Dosing 5 Days on / 2 Days Off | Time to Reach Cmax at Steady State (Tmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 2.02 Hour |
| Part 1A PF-06873600 50 mg BID | Time to Reach Cmax at Steady State (Tmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 3.49 Hour |
| Part 1B PF-06873600 25 mg BID Immediate Release (IR)/Fulvestrant Combination | Time to Reach Cmax at Steady State (Tmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 1.97 Hour |
| Part 1B PF-06873600 25 mg BID IR/Letrozole Combination | Time to Reach Cmax at Steady State (Tmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 2.52 Hour |
| Part 1C PF-06873600 MR 20 IR 25 mg BID | Time to Reach Cmax at Steady State (Tmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 2.00 Hour |
| Part 1C PF-06873600 MR 30 mg BID Long Release | Time to Reach Cmax at Steady State (Tmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 10.0 Hour |
| Part 2A PF-06873600 25 mg BID IR/Fulvestrant Combination | Time to Reach Cmax at Steady State (Tmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 1.98 Hour |
| Part 2C PF-06873600 25 mg BID IR/Fulvestrant Combination | Time to Reach Cmax at Steady State (Tmax) of PF-06873600 Following a Single Oral Dose of Study Intervention on Cycle 1 Day 1 - Part 1 + Part 2 | 1.94 Hour |